Clinical Trials

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06136650 2026-04-15

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT03395197 2026-04-07

TALAPRO-2

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT04076059 2026-02-06

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT04934722 2025-10-01

KEYNOTE-991

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT06520345 2025-07-10

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

430 enrolled

Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 2 FDA

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03851640 2025-03-12

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

417 enrolled

MCRPC

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 3 Terminated

104 enrolled

Prostate Cancer Metastatic

NCT03016312 2024-08-09

IMbassador250

759 enrolled 22 charts

Prostatic Neoplasms, Castration-Resistant

NCT04844749 2024-02-05

VERACITY

Phase 3 Terminated

105 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 3 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02438007 2023-03-15

ARMOR3-SV

Phase 3 Terminated

953 enrolled

Prostatic Neoplasms

NCT01212991 2020-03-17

PREVAIL

1,717 enrolled 20 charts

Prostatic Neoplasms

NCT00974311 2018-12-11

AFFIRM

1,199 enrolled 24 charts